市場調查報告書
商品編碼
1347691
高內容放映市場:2023-2028 年全球行業趨勢、佔有率、規模、成長、機遇和預測High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球高內容放映市場規模達到12億美元。展望未來,IMARC Group預計到2028年該市場將達到20億美元,2023-2028年年複合成長率(CAGR)為8.4%。
高內涵篩選(HCS),也稱為高內涵分析(HCA),是一種識別細胞表現型和生物學偏差的自動顯微鏡方法。它有助於確定候選藥物是否能改變病程,並識別改變細胞形態和表現型的小分子,例如肽或 RNAi。它是藥物發現中基於細胞的篩選的先進方法,結合了多色螢光成像的自動記錄和高通量定量數據分析。它允許專業人員篩选和評估化合物對多個表觀遺傳標記的活性。因此,HCS 廣泛應用於製藥和生物技術公司、學術和政府機構以及契約研究組織 (CROS)。
阿滋海默症和帕金森氏症等慢性疾病和神經退行性疾病的患病率不斷上升,是積極影響全球 HCS 需求的主要因素之一。此外,人口老齡化加劇,更容易患此類疾病,也促進了市場的成長。除此之外,領先企業正在推出與軟體平台和人工智慧(AI)系統整合的創新HCS設備,以提高篩查系統的可視化能力。這也可以歸因於分析細胞分離和可擴展性的自動化系統的發展,這進一步提高了 HCS 技術的採用。此外,由於對負擔得起的藥物發現系統的需求不斷增加,它們在製藥行業中得到了廣泛的應用。除此之外,許多國家的管理機構正在大力投資先進篩查系統的研發(R&D),以及醫療基礎設施的顯著改善,這創造了積極的市場前景。
The global high content screening market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.
High content screening (HCS), also known as high-content analysis (HCA), is an automated microscopy method of identifying cellular phenotype and biological deviations. It assists in determining whether a drug candidate modifies the disease course and identifying micro-molecules such as peptides or RNAi that alter the cell morphology and phenotype. It is an advanced approach to cell-based screening in drug discovery, which combines the automated recording of multicolor fluorescence imaging and high-throughput quantitative data analysis. It allows professionals to screen and evaluate the activity of compounds on multiple epigenetic marks. As a result, HCS is widely used in pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations (CROS).
The increasing prevalence of chronic disorders and neurodegenerative diseases, such as Alzheimer's and Parkinson's, represents one of the major factors positively influencing the demand for HCS around the world. In addition, the rising aging population, which is more prone to such ailments, is contributing to the market growth. Apart from this, leading players are introducing innovative HCS equipment that is integrated with software platforms and artificial intelligence (AI) systems to improve the visualization capabilities of the screening systems. It can also be attributed to the development of automated systems for analyzing cell separation and scalability, which has further improved the adoption of HCS technology. Furthermore, they find extensive application in the pharmaceutical industry due to the escalating need for an affordable drug discovery system. Besides this, governing agencies of numerous countries are considerably investing in the research and development (R&D) of advanced screening systems, along with significant improvement in the healthcare infrastructure, which is creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global high content screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end-user.
Instruments
Cell Imaging and Analysis Systems
Flow Cytometers
Consumables
Reagents & Assay Kits
Microplates
Other Consumables
Software
Services
Accessories
Instruments dominate the market due to advances in instrumentation and automation techniques with advanced visualization capability and enhanced software platforms.
Target Identification and Validation
Primary Screening and Secondary Screening
Toxicity Studies
Compound Profiling
Other Applications
Primary screening and secondary screening currently dominates the market as primary screening helps in determining the microorganisms and organic acid in cells, whereas secondary screening assists in obtaining the quantitative and qualitative information about the cells, desired organisms or strains.
Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)
High content screening (HCS) is widely utilized in pharmaceutical and biotechnology companies for various clinical and preclinical studies.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America holds the majority of the global high content screening share due to the increasing drug discovery research in the region.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific and Yokogawa Electric Corporation.